Tarsus Pharmaceuticals (TARS) Total Non-Current Liabilities (2019 - 2026)

Tarsus Pharmaceuticals' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $216.1 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $216.1 million in Q1 2026; TTM through Mar 2026 was $216.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $208.1 million, up 36.52% from the prior year.
• Total Non-Current Liabilities rose to $216.1 million in Q1 2026 per TARS's latest filing, from $208.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $216.1 million in Q1 2026 and bottomed at $31.0 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $66.8 million (2023), against an average of $95.2 million.
• Across the five-year window, Total Non-Current Liabilities jumped 224.45% in 2022 and increased 18.81% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $34.9 million in 2022, then soared by 91.48% to $66.8 million in 2023, then soared by 128.38% to $152.5 million in 2024, then soared by 36.52% to $208.1 million in 2025, then increased by 3.83% to $216.1 million in 2026.
• Per Business Quant, the three latest TARS Total Non-Current Liabilities figures stand at $216.1 million (Q1 2026), $208.1 million (Q4 2025), and $189.3 million (Q3 2025).